Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 11, 2024

Primary Completion Date

January 1, 2025

Study Completion Date

January 1, 2025

Conditions

Triple-negative Breast Cancer

Interventions

DRUG

Inosine

oral inosine 200mg tid

DRUG

Taxane/Anthracycline/Eribulin Mesylate/Vinorelbine/Capecitabine/Carboplatin/UTD1/platinum

Trial Locations (1)

breast cancer institute of Fudan University Cancer Hospital, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER

NCT06355024 - Inosine Reverse Chemo Resistance in Triple Negative Breast Cancer | Biotech Hunter | Biotech Hunter